Special Issue "Drug Safety and Pharmacovigilance"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (15 September 2012)
Dr. Tomomi Kimura
Head of Epidemiology, Janssen Pharmaceutical K.K., 5-2, Nishi-kanda 3-chome, Chiyoda-ku, Tokyo 101-0065, Japan
Phone: +81 3 4411 5958
Interests: clinical epidemiology; database research; ethnic sensitivities
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- drug safety
- active surveillance
- signal detection
Article: Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
Pharmaceutics 2012, 4(3), 479-493; doi:10.3390/pharmaceutics4030479
Received: 11 June 2012; in revised form: 8 August 2012 / Accepted: 30 August 2012 / Published: 19 September 2012| Download PDF Full-text (240 KB) | Download XML Full-text
Pharmaceutics 2012, 4(4), 607-640; doi:10.3390/pharmaceutics4040607
Received: 4 September 2012; in revised form: 15 November 2012 / Accepted: 26 November 2012 / Published: 13 December 2012| Download PDF Full-text (456 KB) | Download XML Full-text
Article: Safety Monitoring in Clinical Trials
Pharmaceutics 2013, 5(1), 94-106; doi:10.3390/pharmaceutics5010094
Received: 6 November 2012; in revised form: 9 January 2013 / Accepted: 10 January 2013 / Published: 17 January 2013| Download PDF Full-text (442 KB) | Download XML Full-text
Commentary: Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities
Pharmaceutics 2013, 5(1), 168-178; doi:10.3390/pharmaceutics5010168
Received: 31 December 2012; in revised form: 16 February 2013 / Accepted: 18 February 2013 / Published: 12 March 2013| Download PDF Full-text (165 KB) | Download XML Full-text
Article: Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic
Pharmaceutics 2013, 5(1), 179-200; doi:10.3390/pharmaceutics5010179
Received: 6 November 2012; in revised form: 1 March 2013 / Accepted: 4 March 2013 / Published: 14 March 2013| Download PDF Full-text (262 KB) | Download XML Full-text
Last update: 17 December 2012